A rre company.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Living with Fabry
“It has been 15 years since a treatment was approved in the U.S. for people with Fabry disease. We’re excited to have a second option available for some people living with Fabry Disease.”
Founder & President
National Fabry Disease Foundation
Inventive science is at the core
of our technology platforms.
Living with Pompe
News & Announcements
August 8, 2019
August 2, 2019
Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
August 1, 2019
Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
July 2, 2019
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
July 1, 2019
International NewsBiogen and Amicus Win UK Prix Galien Prizes as Orphan Diseases Take Centre Stage New treatment for Fabry disease to be listed on Australia’s Life Saving Drugs Program More news
A Rare Company - Bold Commitment
Every day at Amicus we strive to fulfill the bold commitment we’ve made to the rare disease community. This commitment keeps us at the forefront of innovation as we work to develop medicines for those who need them most.
A Rare Company – Persistence & Resilience
At Amicus Therapeutics, we believe that we should never give up on our mission to help people with rare diseases. This video in our #RareCompany series talks about the importance of persistence & resilience in our daily work of developing medicines and serving the rare disease community.
A Rare Company – Extraordinary Patient Focus
At Amicus, patient-centricity is in our DNA. See how our commitment to patients goes further than just our medicines and expands out to the rare disease community at large.